How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Arcutis Biotherapeutics is back in focus as price targets cluster around $35, with at least one firm trimming its view from $37 to $35 while others move targets from the low $30s to the mid $30s. Analysts are weighing Q4 results, higher full year and 2026 guidance, and the role of Zoryve in these updates. Together, these factors help explain why expectations are converging near the same level. Read on to see how to track these shifts and keep up with the evolving analyst narrative around the stock. Stay updated as the Fair Value for Arcutis Biotherapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Arcutis Biotherapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Morgan Stanley, TD Cowen, Guggenheim, and H.C. Wainwright all cluster around a US$34 to US$35 price target, which points to a tighter range of views on valuation. Morgan Stanley highlights Q4 sales that came in ahead of its
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewswire
- Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? [Yahoo! Finance]Yahoo! Finance
- Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Arcutis Biotherapeutics (ARQT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 3/26/26 - Form SCHEDULE
- ARQT's page on the SEC website